

FANCG RABBIT PAB

货号: S217427

产品全名: FANCG 兔多抗

基因符号: FAG; XRCC9

UNIPROT ID: O15287 (Gene Accession - BC000032)

背景: The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCI (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group G.

抗原: Fusion protein of human FANCG

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 1000-2000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human cervical cancer tissue using 217427(FANCG Antibody) at a dilution of 1/30(Nucleus or Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with the fusion protein and then with 217427(Anti-FANCG Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffin-embedded Human colon cancer tissue using 217427(Anti-FANCG Antibody) at a dilution of 1/30.



In comparison with the IHC on the left, the same paraffin-embedded Human colon cancer tissue is first treated with fusion protein and then with D222844(Anti-FANCG Antibody) at dilution 1/30.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
